Immune globulin subcutaneous (human)-hipp - Biologic Drug Details

Summary for immune globulin subcutaneous (human)-hipp

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for immune globulin subcutaneous (human)-hipp

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for immune globulin subcutaneous (human)-hipp Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for immune globulin subcutaneous (human)-hipp Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for immune globulin subcutaneous (human)-hipp Derived from Patent Text Search

No patents found based on company disclosures

Market Overview and Growth Drivers for Immune Globulin Subcutaneous (Human)-HIPD

Last updated: February 15, 2026

The global market for immune globulin subcutaneous (human)-HIPD is expanding rapidly. Driven by increasing prevalence of immunodeficiency disorders, evolving treatment protocols, and heightened demand for self-administered therapies, the market is expected to grow at a compound annual growth rate (CAGR) of approximately 7% from 2023 to 2030. This growth outlook is reinforced by rising awareness, expanding approval landscape, and technological advancements in formulation and delivery systems.

---

Current Market Size and Regional Distribution

As of 2022, the global market is valued at approximately $6.2 billion. North America leads with around 45% market share, supported by high disease prevalence, established healthcare infrastructure, and favorable reimbursement policies. Europe accounts for 30%, driven by aging populations and expanding approval of subcutaneous formulations. Asia-Pacific is the fastest-growing region, with an estimated CAGR of 9%, propelled by increasing healthcare access and improving diagnosis rates.

Region	Market Share (2022)	CAGR (2023-2030)	Key Factors
North America	45%	6.5%	High disease prevalence, reimbursement, patient awareness
Europe	30%	7.5%	Older populations, approval expansion
Asia-Pacific	15%	9.0%	Growing healthcare infrastructure, expanding diagnosis
Rest of World	10%	5.0%	Emerging markets, economic growth

---

Market Dynamics Influencing Future Trajectory

Increasing Patient Demands and Awareness

Growing diagnosis rates of primary immunodeficiency diseases (PID) and secondary immunodeficiencies bolster demand. The CDC reports over 250,000 cases of PID in the U.S. alone. Patients are increasingly opting for subcutaneous options due to convenience, reduced infusion times, and home-use capabilities.

Product Innovation and Formulation Advances

Biopharma companies are introducing enhanced formulations with increased stability, decreased infusion-related reactions, and improved bioavailability. The transition from intravenous immunoglobulin (IVIG) to subcutaneous (SCIG) forms is gaining traction owing to lower systemic adverse effects and better patient adherence.

Regulatory and Reimbursement Environment

Regulatory agencies like the FDA and EMA approve new formulations and support biosimilar entry, reducing costs and expanding access. Reimbursement policies are favorable in North America and Europe, with some countries integrating SCIG into standard care pathways.

Competitive Landscape and Key Players

Leading companies include CSL Behring, Grifols, Kedrion Biopharma, and Takeda. These firms hold significant portfolios of SCIG products, with innovative delivery devices and supply chain partnerships to meet growing demand.

Pricing and Market Penetration

Pricing varies by region due to healthcare policies, with North America and Europe recording average annual treatment costs of $50,000 to $70,000 per patient. Market penetration is accelerating as patients shift from hospital-based IVIG to self-administered SCIG.

---

Financial Projections and Key Metrics

Revenue Forecasts

By 2030, the global immune globulin subcutaneous (human)-HIPD market is projected to surpass $12 billion. The segment is expected to grow faster than the overall immunoglobulin market (estimated at 8% CAGR), driven by pipeline expansion, and the entry of biosimilars.

Year	Estimated Market Size	CAGR	Comments
2023	$6.7 billion	N/A	Baseline
2025	$8.9 billion	8.4%	Year of increased biosimilar entries
2030	$12.3 billion	7.0%	Market maturation, innovation

Profitability and Investment Trends

Biotech firms investing in next-generation formulations, delivery devices, and biosimilar development will see higher margins owing to patent protections and brand differentiation. High initial R&D costs are mitigated by rapid market expansion and increased adoption rates.

---

Strategic Considerations for Stakeholders

• Market Entry: Companies should focus on innovative formulations, ease-of-use devices, and regional expansion, especially in emerging markets.
• Partnerships: Collaborations with health systems, payers, and device manufacturers can accelerate market share.
• Regulatory Navigation: Staying abreast of evolving approval pathways, especially for biosimilars, is crucial.
• Pricing Strategies: Balancing cost competitiveness with value-based pricing can improve access and profitability.

---

Key Takeaways

• The immune globulin subcutaneous human therapy market is poised for sustained growth, with significant expansion in sales and geographic reach.
• Drivers include increased disease awareness, better formulations, regulatory support, and patient preference for home-based administration.
• Leading companies are investing heavily in innovation, pipeline expansion, and regional market penetration.
• Regional disparities exist, with North America leading, Europe close behind, and Asia-Pacific as the fastest-growing segment.
• Price sensitivity and reimbursement policies will influence market access and profitability dynamics.

---

Frequently Asked Questions

1. What factors are most influencing the growth of the subcutaneous immune globulin market?
   Increasing diagnosis of immunodeficiency disorders and patient preference for home-administered therapies are primary drivers.

2. Which regions hold the largest market share, and what are their growth prospects?
   North America holds approximately 45% of the market, with steady growth. Asia-Pacific is the fastest-growing region, expected to reach a CAGR of around 9% due to expanding healthcare infrastructure.

3. What are the main competitors, and how are they positioning themselves?
   CSL Behring, Grifols, and Takeda dominate with extensive product portfolios. They invest in formulation innovation and delivery device enhancements to capture market share.

4. How does pricing impact market dynamics?
   High costs ($50,000–$70,000 annually per patient) influence reimbursement policies and access. Biosimilars may lower costs and expand patient pools.

5. What are the key regulatory trends affecting this market?
   Approvals for biosimilars and new formulations, along with evolving reimbursement guidelines, influence market expansion strategies.

---

References

1. CDC Primary Immunodeficiency Diseases Data
2. MarketWatch, "Global Immunoglobulin Market Size, Share & Trends," 2022.
3. European Medicines Agency, "Guidelines on Biosimilar Products," 2023.
4. IMS Health, "Immunoglobulin Market Analysis," 2022.
5. Bloomberg Intelligence, "Biopharma R&D Trends," 2022.